ABOUT THIS EPISODE
Prof David Currow of Flinders University Adelaide, Australia discusses research from a phase III trial at ESMO 2014 surrounding a new drug called Anamorelin for patients with advanced lung cancer. The new drug has been seen to improve appetite and body mass by mimicking the effects of the so-called “hunger hormone” ghrelin, which is secreted by the stomach.
English
United States
TRANSCRIPT 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
OTHER EPISODES IN THIS PODCAST
Prof Lefebvre (Northern France Comprehensive Cancer Centre, Lille, France) talks to ecancertv at ESMO 2014 about the Make Sense campaign, and the ways in which they are raising the public's awareness of head and neck cancer.
Dr Swain (Washington Cancer Institute, Washington, USA) talks to ecancertv at ESMO 2014 about the results of the CLEOPATRA trial, which demonstrated significant survival benefits for patients with HER2 breast cancer when treated with a combination of pertuzumab, trastuzumab and chemotherapy.
Prof Meunier, Director General of the European Organisation for Research and Treatment of Cancer, Belgium (EORTC) talks to ecancertv at ESMO 2014 about the financial impacts of cancer and the quality of life issues associated with them.
Dr Symonds (University Hospital of Leicester, Leicester, UK) talks to ecancertv at ESMO 2014 about his work looking at the use of experimental, drug cediranib, in the treatment of cervical cancer.
ecancer's Gordon McVie talks to Anastassia Negrouk, of the European Organisation for Research and Treatment of Cancer (EORTC), at ESMO 2014 on managing data in clinical trials and encouraging more personalised medicine to take place for the progression of cancer care.
Disclaimer: The podcast and artwork embedded on this page are from ecancer, which is the property of its owner and not affiliated with or endorsed by Listen Notes, Inc.
EDIT
Thank you for helping to keep the podcast database up to date.